Esophageal Varices: Causes, Symptoms, Diagnosis, Treatment, and Prevention


Esophageal Varices Illustration

Esophageal varices are dilated veins in the lower part of the esophagus that develop in the setting of portal hypertension. Most often, they occur in people with severe liver disease such as cirrhosis, because scar tissue blocks normal blood flow through the liver. When pressure rises in the portal vein, blood is rerouted into smaller vessels that are not designed for high volume. This causes these blood vessels in the esophagus to enlarge and become fragile. Untreated esophageal varices can rupture and cause serious bleeding, which requires emergency treatment.

Causes and Risk Factors

The main cause of esophageal varices is longstanding liver disease that leads to portal hypertension. Risk factors include:

Signs and Symptoms

Esophageal varices themselves often cause no symptoms until they bleed. When bleeding occurs, symptoms may include:

In the absence of bleeding, patients may have signs of underlying liver disease such as:

Diagnosis of Esophageal Varices

Endoscopic Evaluation

The gold standard for detecting and grading esophageal varices is upper endoscopy. A flexible tube with a camera is inserted through the mouth to directly visualize the veins. Varices are graded based on size:

Imaging and Noninvasive Tests

In addition to endoscopy, the following studies can assess liver health and portal pressure:

Treatment to Prevent Bleeding

Once esophageal varices are identified, the primary goal is to lower portal pressure and prevent variceal bleeding:

Management of Acute Variceal Bleeding

Acute bleeding from esophageal varices is a life-threatening emergency. Key steps in management include:

  1. Resuscitation: Establish two large-bore IV lines, transfuse blood products, correct coagulopathy, and maintain airway protection.
  2. Vasoactive drugs: Initiate octreotide or terlipressin to constrict splanchnic vessels and reduce portal pressure.
  3. Emergency endoscopy: Perform as soon as the patient is hemodynamically stable. Use band ligation as first-line therapy for bleeding varices.
  4. Balloon tamponade or Sengstaken-Blakemore tube: Use only as a bridge to definitive therapy if endoscopic control is not possible.
  5. Antibiotic prophylaxis: Administer intravenous ceftriaxone or norfloxacin to reduce infection risk in cirrhotic patients.
  6. TIPS placement: Consider early in patients who fail endoscopic and pharmacologic therapy to control bleeding.

Prevention and Long-Term Management

Lifestyle and Dietary Measures

Although you cannot reverse established cirrhosis, certain actions can help reduce portal hypertension progression and lower variceal risk:

Regular Surveillance Endoscopy

Patients with cirrhosis should undergo screening endoscopy every 1–2 years to detect new or worsening varices. If small varices are found, repeat endoscopy is recommended in 1–2 years. For those with medium or large varices, start primary prophylaxis with β-blockers or EVL immediately.

Conclusion

Esophageal varices represent a serious complication of portal hypertension. Early detection through endoscopy, appropriate use of nonselective β-blockers and endoscopic band ligation, and lifestyle modifications can greatly reduce the risk of life-threatening bleeding. If bleeding occurs, prompt resuscitation, vasoactive therapy, and endoscopic intervention are critical. For patients with refractory variceal bleeding, TIPS placement provides an effective means of reducing portal pressure. Work closely with a hepatology or gastroenterology specialist to develop an individualized management plan.

Disclaimer: This article is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content provided should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any decisions about your health or medical conditions. Never disregard or delay seeking professional medical advice due to the information provided in this article. The author and publisher of this article are not responsible or liable for any adverse outcomes resulting from the use or reliance on the information provided herein.